DMAA
Drugs Made In·NASDAQ
--
--(--)
--
--(--)
DMAA fundamentals
During Q3 2025, Drugs Made In (DMAA) reported revenue of --, a YoY change of 0.00%. Net income was 2.18M, a YoY change of 1607.34%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | TTM |
|---|
Start Date | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | -- |
End Date | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Operating Expenses | 144.93K -- | 79.99K -- | 330.93K -- | 131.92K -- | 263.70K +81.95% | 806.53K -- |
Selling, General and Administrative Expenses | 144.93K -- | 79.99K -- | 330.93K -- | 131.92K -- | 263.70K +81.95% | 806.53K -- |
General and Administrative Expenses | 144.93K -- | 79.99K -- | 330.93K -- | 131.92K -- | 263.70K +81.95% | 806.53K -- |
Operating Income | -144.93K -- | -79.99K -- | -330.93K -- | -131.92K -- | -263.70K -81.95% | -806.53K -- |
Non-Operating Income (Loss) | 0 -- | 0 -- | 1.59M -- | 2.42M -- | 2.45M -- | 6.45M -- |
Net Interest Expense | 0 -- | 0 -- | -1.59M -- | -2.42M -- | -2.45M -- | -6.45M -- |
Interest Income | 0 -- | 0 -- | 1.59M -- | 2.42M -- | 2.45M -- | 6.45M -- |
Pretax Income From Continuing Operations | -144.93K -- | -79.99K -- | 1.25M -- | 2.29M -- | 2.18M +1607.34% | 5.65M -- |
Net Income | -144.93K -- | -79.99K -- | 1.25M -- | 2.29M -- | 2.18M +1607.34% | 5.65M -- |
Net Income Attributable to Owners of the Company | -144.93K -- | -79.99K -- | 1.25M -- | 2.29M -- | 2.18M +1607.34% | 5.65M -- |
Net Income Attributable to Common Stockholders | -144.93K -- | -79.99K -- | 1.25M -- | 2.29M -- | 2.18M +1607.34% | 5.65M -- |
Total Comprehensive Income Attributable to Owners of the Company | -- -- | -279.85K -- | -- -- | 2.29M -- | -- -- | -- -- |
Basic EPS | -- -- | -- -- | 0.04 -- | 0.07 -- | 0.07 -- | -- -- |
Basic EPS from Continuing Operations | -0.02 -- | -- -- | 0.05 -- | 0.07 -- | 0.07 +450.00% | -- -- |
Diluted EPS | -- -- | -- -- | 0.04 -- | 0.07 -- | 0.07 -- | -- -- |
Diluted EPS from Continuing Operations | -0.02 -- | -- -- | 0.05 -- | 0.07 -- | 0.07 +450.00% | -- -- |
You can ask Aime
What were the key takeaways from Drugs Made In’s earnings call?What guidance did Drugs Made In's management provide for the next earnings period?What does Drugs Made In do and what are its main business segments?What is Drugs Made In's gross profit margin?Did Drugs Made In beat or miss consensus estimates last quarter?What is the revenue and EPS growth rate for Drugs Made In year over year?What were the key takeaways from Drugs Made In's earnings call?What factors drove the changes in Drugs Made In's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
